Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2010; 5(10): e13216.
Published online 2010 October 12. doi:  10.1371/journal.pone.0013216
PMCID: PMC2953493

Brn2 Is a Transcription Factor Regulating Keratinocyte Differentiation with a Possible Role in the Pathogenesis of Lichen Planus

Jürgen Schauber, Editor


Terminal differentiation of skin keratinocytes is a vertically directed multi-step process that is tightly controlled by the sequential expression of a variety of genes. In this study, we investigated the role of the POU domain-containing transcription factor Brn2 in keratinocyte differentiation. Immunohistochemical analysis showed that Brn2 is expressed primarily in the upper granular layer. Consistent with its epidermal localization, Brn2 expression was highly induced at 14 days after calcium treatment of cultured normal human epidermal keratinocytes. When Brn2 was overexpressed by adenoviral transduction, Brn2 led to increased expression of the differentiation-related genes involucrin, filaggrin, and loricrin in addition to inhibition of their proliferation. Chromatin immunoprecipitation demonstrated that Brn2 bound to the promoter regions of these differentiation-related genes. We injected the purified Brn2 adenovirus into rat skin, which led to a thickened epidermis with increased amounts of differentiation related markers. The histopathologic features of adenovirus-Brn2 injected skin tissues looked similar to the features of lichen planus, a human skin disease showing chronic inflammation and well-differentiated epidermal changes. Moreover, Brn2 is shown to be expressed in almost all cell nuclei of the thickened epidermis of lichen planus, and Brn2 also attracts T lymphocytes. Our results demonstrate that Brn2 is probably a transcriptional factor playing an important role in keratinocyte differentiation and probably also in the pathogenesis of lichen planus lesions.


Terminal differentiation of skin keratinocytes, in which the transition from basal keratinocytes to corneocytes is occurred, is a complex process that requires the simultaneous activation and inactivation of a wide variety of genes that must be expressed at the correct time and in the correct location [1]. Some characteristic genes expressed at different stages of keratinocyte maturation, such as involucrin, loricrin and filaggrin, are well documented [2]. In addition, a number of ubiquitous transcription factors, such as AP1, Sp1, and the AP2 family members, are involved in regulating keratinocyte gene expression and differentiation [3]. Although the functional involvement of many transcription factors in keratinocyte differentiation has been known, however, it is not sufficient to understand the sophisticated regulatory mechanism underlying this process. In this study, we identify a POU domain-containing transcription factor Brn2 as an important regulator in keratinocyte differentiation.

POU domain proteins have been implicated in development, replication, growth and cell cycle arrest, and differentiation [4][6]. Especially, POU domain-containing transcription factor Brn2 (also called N-Oct3 and POU3F2) has been implicated in both neuronal differentiation and activation of the corticotrophin-releasing hormone gene [7][9]. Targeted disruption of the Brn2 gene in mice results in loss of specific neuronal lineages in the hypothalamus and consequent loss of the posterior pituitary gland [9], [10]. Brn2 negative mice, therefore, die within 10 days of birth, although the specific cause of death is not apparent. As for skin cells, evidence also implicates it in melanoma growth and survival. Brn2 is overexpressed in human melanoma cell lines compared to normal melanocytes [11], [12], and it appears to play a role in melanoma cell proliferation and tumorigenesis [13], [14]. In melanoma, Brn2 is a focus for convergence of the MAP kinase and Wnt/β-catenin signaling pathways that are linked to cell proliferation [15], [16]. However, the expression and putative role of Brn2 in keratinocytes have not been clearly elucidated yet.

Although the importance of Brn2 in neuronal differentiation and melanoma development is recognized, however, the expression and putative role of Brn2 in epidermal keratinocytes have not been clearly elucidated yet. In this study, we provide evidences that Brn2 is a transcriptional factor playing an important role in keratinocyte differentiation, and probably also in the pathogenesis of lichen planus lesions.


Expression of Brn2 in epidermal keratinocytes

To investigate the Brn2 expression during keratinocyte differentiation, we adopted a well-established calcium-induced differentiation model [17]. RT-PCR analysis clearly showed that the expression of Brn2 was increased at 14 days after calcium treatment (Figure 1A). Protein analysis using Western blotting also identified endogenous Brn2 expression in 14 day induced cells (Figure 1B). Consistent with, immunohistochemistry showed that Brn2 expression was increased in the granular layer of the epidermis (Figure 1C).

Figure 1
Expression of Brn2 in epidermal keratinocytes.

Brn2 regulates the expression of keratinocyte differentiation markers

Since the expression of Brn2 was increased in the granular layer of the epidermis as well as in the differentiated keratinocytes by calcium, we speculated that Brn2 has a role for keratinocyte differentiation. To test this idea, we made the recombinant adenovirus expressing green fluorescent protein-tagged Brn2 (GFP-Brn2), and transduced cultured human epidermal keratinocytes. When overexpressed, Brn2 was located in nuclei of keratinocytes (Figure 2A). We then determined the effect of Brn2 on the expression of keratinocyte differentiation markers. As shown in Figure 2B, Brn2 increased expression of keratinocyte differentiation markers involucrin, loricrin, and filaggrin. The same results were obtained at protein levels (Figure 2C). To determine whether Brn2 effect was at the promoter level, we transduced keratinocytes with involucrin-luc reporter adenoviruses, in which about 3.7 kb of involucrin promoter fragment was fused to luciferase gene. Overexpression of Brn2 significantly increased the luciferase activities, in both the absence and presence of calcium (Figure 2D).

Figure 2
Keratinocyte differentiation by Brn2.

To further verify whether Brn2 directly regulates the transcription of differentiation-related genes, we searched for Brn2-binding site(s) using UCSC Genome Bioinformatics Program search engines and the Computational Biology Research Center program ( As a result, we found the putative Brn2-binding sites from promoters of involucrin, loricrin and filaggrin genes (Figure 3A). Consecutive chromatin immunoprecipitation (ChIP) assay clearly revealed that Brn2 bound to the promoters of involucrin, loricrin and filaggrin genes (Figure 3B). These results indicate that Brn2 is a functional transcription factor directly involved in the expression of involucrin, loricrin and filaggrin.

Figure 3
Chromatin Immunoprecipitation (ChIP) assay.

Brn2 reduces the growth of keratinocytes

Keratinocyte proliferation assays were performed to determine the effects of Brn2 on the keratinocyte growth. Keratinocytes were plated at a low density and after transduction with Brn2 adenovirus, grown for 3 days. The proliferation rate was determined using a thymidine assay. When Brn2 was overexpressed in keratinocytes, significant retardation of cell growth was observed (Figure 4A). To investigate how Brn2 affects the cell cycle, we determined which components of cell cycle-controlling molecules were affected by Brn2. As shown in Figure 4B, Brn2 increased the expression of the cell cycle regulators such as p53, p21 and Rb, while it decreased expression of PCNA.

Figure 4
Effect of Brn2 on the growth of keratinocytes.

Brn2 increases the epidermal thickness and induces keratinocyte differentiation after intra-dermal injection into rat skin

We performed in vivo intra-dermal injection of the purified Brn2 adenovirus into rat skin. One week after injection, the thickness of the rat epidermis was increased to 6 to 8 cells, compared with 3–4 cells for uninjected skin or skin injected with either the PBS or GFP adenovirus (Figure 5A). Consistent with the predominant effects of Brn2 on the differentiation of cultured keratinocytes, epidermal layers expressing keratin10 and loricrin were increased by intra-dermal injection of Brn2 adenovirus (Figure 5B). Expression of keratin 14 was not significantly different between control- and Brn2-injected rat skin. There was no difference in the number of positive cells in the basal layer stained with the proliferation markers, anti-PCNA and anti-p63 antibodies. However, p21-expressing layers were significantly increased (Figure 5C). These results are not consistent with the decreased proliferation rate of keratinocytes transduced with Brn2 adenovirus (Figure 4A). Inconsistent results between in vitro cell cultures overexpressing Brn2 and in vivo data are thought due to other unknown in vivo factors that counteract the effect of Brn2.

Figure 5
Ectopic expression of Brn2 in rat skin.

Brn2 intra-dermal injected rat skin is similar to lichen planus

Although it was not all the case, the histopathology of Brn2 injected skin in some mice was similar to human lichen planus. Lichen planus is a well-known immunologically mediated skin reaction resulting in 1) hyperparakeratosis with thickening of the granular and spinous cell layers, 2) degeneration of the basal cell layer, and 3) infiltration of inflammatory cells into the subepithelial layer of connective tissue (Figure 6A). We examined the expression of Brn2 in the skin lesions of lichen planus and found that Brn2-expressing epidermal layers were highly increased in lichen planus compared to normal skin (Figure 6B). Lichen planus is a T-cell-mediated chronic inflammatory disease of unknown etiology. The lymphocytic infiltrates in lichen planus are composed almost exclusively of T-cells, and the majority of T-cells are activated CD3+ and CD8+ lymphocytes [18][21]. Consistent with this notion, CD3 positive T cells were infiltrated in the skin of the Brn2 adenovirus injected rat (Figure 6B). Thus, we hypothesized that Brn2-overexpressing keratinocytes may have impact on T cell migration. To test this idea, we used a chemotaxis assay with Jurkat T cells using a modified Boyden chamber analysis. Brn2-transduced keratinocytes attracted Jurkat T cells at about 6 fold greater than that of GFP-transduced keratinocytes (Figure 7). Thus, our results provide the first evidence that Brn2 has a role in the pathogenesis of lichen planus by promotion of T lymphocyte migration and by mediation of keratinocyte differentiation.

Figure 6
The histopathology of Brn2-injected epidermis is similar to human lichen planus.
Figure 7
Brn2 induced chemotaxis of T lymphocyte migration.


In this study, we demonstrated that Brn2 mRNA and protein levels were increased in 14 days after calcium treatment of primary keratinocytes, consistent with its exclusive expression in the granular layer of the normal epidermis. Using a recombinant adenovirus technique, we showed that Brn2 has a potential for promoting the keratinocyte differentiation. Actually, Brn2 induced the expression of differentiation markers such as involucrin, loricrin and filaggrin. These effects were believed to be a consequence of direct binding of Brn2 to the promoters of such genes, evidenced by ChIP assay. The most frequent targets of the POU domain proteins are the “octamer” motifs (ATGCAAAT), which are involved in both ubiquitous and cell-type specific regulation of various genes [11], [22]. These proteins also have the flexibility to bind heterogeneous sequences, such as the so-called TAATGARAT motif [22]. The proximal promoter region of the human profilaggrin gene contains two AT-rich motifs that are homologous to the consensus recognition sequence TAATGARAT of the POU domain transcription factors [23], [24]. In our study, the Brn2 binding motifs of the involucrin, loricrin and filaggrin promoter regions are not the same as the Oct binding motifs. However, they do have AT-rich motifs and nearly all binding sites have the same ATTTT motifs. Therefore, Brn2 increases differentiation of keratinocytes through increased transcriptional activity via specific DNA binding to the promoter regions of differentiation-related genes.

Despite its potential for promoting the keratinocyte differentiation, in our study, the epidermal thickness of Brn2-injected rat skin significantly increased with the increased differentiation in the spinous and granular layers. Brn2 markedly inhibited cell proliferation when overexpressed in cultured keratinocytes, however cell proliferation in the basal layer looked like unaffected by Brn2-injecton in rat skin. The discrepancy between in vitro and in vivo data regarding cell proliferation remains to be elucidated. Interestingly, in keap1-null mice, epidermal thickness is increased along with the increased differentiation marker expression [25]. These results suggest that epidermal thickness is determined by the balance of keratinocyte proliferation and differentiation, and it is likely that the impairment of the balance between proliferation and differentiation could lead to the thickening of epidermis.

Since intradermal injection of adenovirus can transduce almost all cells in the dermis including fibroblasts and possibly immune cells and endothelial cells, there can be paracrine effects by which the changes in the epidermis are happened. Actually, in our preliminary study, overexpression of Brn2 in fibroblasts resulted in increased expressions of IL-6 and IL-8 (Figure S1 and S2). Furthermore, the conditioned medium collected from Brn2-overexpressed fibroblasts induced the growth of keratinocytes as compared with the control conditioned medium (Figure S3). Thus, it is likely that epidermal thickening in Brn2-injected rat skin may be partly linked to the paracrine effects of neighboring cells.

The histopathology of Brn2-injected rat skin was similar to human lichen planus, showing hyperparakeratosis with thickening of the granular cell layer, degeneration of the basal cell layer, and infiltration of inflammatory cells into the subepithelial layer of connective tissue. We demonstrated the Brn2 is highly expressed in almost all epidermal cell nuclei in lichen planus using immunohistochemistry with the anti-Brn2 antibody. High levels of loricrin have been identified in the hypergranulotic and hyperorthokeratotic epidermis of lichen planus in a study exploring molecular alterations in keratinocyte differentiation in lichen planus [26]. Involucrin has also been identified as a diagnostic marker in oral lichenoid lesions based on observations of involucrin reactivity in the skin and in oral lichen planus [27], [28]. There are also reports of high p53 and p21 expression levels in oral lichen planus [29], [30]. We found that overexpression of Brn2 in keratinocytes changed the expressions of involucrin, loricrin, p53 and p21, supporting the notion that Brn2 is closely linked to the pathogenesis of lichen planus.

Lichen planus is a pruritic, papular eruption characterized by a violaceous color, polygonal shape, and, sometimes, a fine scale. It is most commonly found on the flexor surfaces of the upper extremities, on the genitalia, and on mucous membranes. Lichen planus skin lesions are thought to be an immunologically mediated reaction involving T-cells because lichen planus histology is characterized by a dense, subepithelial lympho-histiocytic infiltrate with an increased number of intra-epithelial lymphocytes [31]. As a consequence, degeneration of basal keratinocytes occurs forming colloid (Civatte, hyaline, cytoid) bodies that appear as homogenous eosinophilic globules [32][37]. Brn2 adenoviral injection of rat skin led to detection of CD3 positive lymphocytes in the epidermis, but not in GFP injected or normal control tissues. However, the density of inflammatory cells in Brn2 injected skin was not as high as in lichen planus, which is characterized by a band-like pattern of inflammatory cell infiltration in subepidermal areas, denying the role of Brn2 in the cause of lichen planus. Our observations of rat skin were made after a one time injection with the Brn2 adenovirus. It is possible that Brn2 could attract more inflammatory infiltrates, like in lichen planus, in a model in which Brn2 is continuously produced. It is also possible that inflammation is triggered by other mechanisms that induce Brn2 expression in keratinocytes. Such mechanisms may exaggerate inflammation while inducing terminal differentiation via positive feed back cycles.

The lymphocytic infiltrates of lichen planus are composed almost exclusively of T-cells with a high expression level of CD3+ on the cell surface [38]. While the majority of T-cells within the epithelium and adjacent to damaged basal keratinocytes is activated CD8+ lymphocytes with cytotoxic effects, most lymphocytes in the lamina propria are CD4+ helper T-cells lacking cytotoxic effects [18], [20], [39]. We also detected CD3 positive lymphocytes in Brn2 adenovirus injected rat skin, but not in GFP injected control tissues. Most inflammatory cells were observed in the upper dermis with a few approaching the epidermis. Some basal keratinocytes exhibited vacuolar changes, which probably indicates the beginning of lichen planus. Altogether, these results suggest that Brn2 may have a role for pathogenesis of lichen planus. The precise relationship between Brn2 and lichen planus, however, remains to be elucidated.

In conclusion, we provide evidence that Brn2 has a role in mediating keratinocyte differentiation, and is possibly linked to pathogenesis of lichen planus. Further research in this area should document what kinds of phenotypes would be followed in the absence of Brn2 expression in the epidermis.

Materials and Methods

Ethics Statement

All human skin samples were obtained under the written informed consent of donors, in accordance with the ethical committee approval process of the Institutional Review Board of Chungnam National University School of Medicine (permit number: 07-07, Development of skin specific microarray for gene analysis of Korean atopic patients). All animal tests were approved by the Institutional Review Board of Chungnam National University School of Medicine (permit number, CNUCOM-2007-14, Development of animal model for atopic dermatitis).

Cell culture

Primary epidermal keratinocytes were cultured according to the method previously reported [40]. Keratinocytes were maintained in keratinocyte-serum free medium (K-SFM) supplemented with epidermal growth factor (EGF) and bovine pituitary extract (Gibco BRL, Rockville, MD). Jurkat T lymphoma cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) (Gibco BRL).

Immunohistochemical staining

Skin samples were fixed in 10% formalin for 24 h and embedded in paraffin. Sections of skin specimens were dewaxed, rehydrated, then washed three times with phosphate-buffered saline (PBS). After treatment with proteinase K (1 mg/ml) for 5 min at 37°C, sections were treated with H2O2 for 10 min at room temperature, placed in a blocking-solution (Dako, Carpinteria, CA) for 20 min, followed by reaction with the appropriate primary antibodies. Sections were incubated sequentially with peroxidase-conjugated secondary antibodies (Upstate, Lake Placid, NY) and visualized using a Chemmate Envision Detection Kit (Dako). Following antibodies were used in this study: Brn2, PCNA, GFP, p63, p21, loricrin, PCNA and CD3+ (SantaCruz Biotechnologies, Santa Cruz, CA); keratin 10, keratin 14 (Babco, Richmond, CA).

Reverse transcription-polymerase chain reaction (RT-PCR)

Total RNAs were isolated from keratinocytes using Easy-blue RNA extraction kit (Intron, Daejeon, Korea). Two µg of total RNAs were reverse transcribed with moloney-murine leukaemia virus (M-MLV) reverse transcriptase (ELPIS Biotech, Daejeon, Korea). Aliquots of RT mixture were subjected to PCR cycles with appropriate primer sets. The sequences for primers were as follows: Brn2, 5′- GGAGTAGGGACACTCCACCA and 5′-CAGGAAGCTGCATTTTGTG; involucrin, 5′-CAAAGAACCTGGAGCAGGAG and 5′-CAGGGCTGGTTGAATGTCTT; loricrin, 5′-GTGGGAGCGTCAAGTACTCC and 5′-AGAGTAGCCGCAGACAGAGC; filaggrin, 5′-GGCACTCATCATGCAGAGAA and 5′- ATGGTGTCCTGACCCTCTTG; cyclophilin, 5′-CTCCTTTGAGCTGTTTGCAG and 5′-CACCACATGCTTGCCATCCA.

Western blot analysis

Cells were lysed in Proprep solution (Intron). Total protein was measured using a Bradford protein assay kit (Bio-Rad Laboratories, Hercules, CA). Samples were run on SDS-polyacrylamide gels, transferred onto nitrocellulose membranes and incubated with appropriate antibodies. Blots were then incubated with peroxidase-conjugated secondary antibodies, visualized by enhanced chemiluminescence (Intron). The following primary antibodies were used in this study: involucrin, loricrin (Santa Cruz Biotechnologies); Rb, p53 (Cell Signaling Technology, Danvers, MA); actin (Sigma, St. Louis, MO).


Aliquot of RT mixture was subjected to PCR cycles with primer set for Brn2 (5′-CGCTACGGATCCATGGCGACCGCAGCGTCTAA and 5′-CGCTACGGATCC TCACTGGACGGGCGTCTGCA). The amplified full-length cDNA for PITX2c was subcloned into pENT/CMV-GFP vector that has attL sites for site-specific recombination with a Gateway destination vector. The replication-incompetent adenoviruses were created using Virapower adenovirus expression system (Invitrogen) according to the method previously described [41]. The adenovirus was purified with cesium chloride according to the method previously reported [42]. For creation of involucrin-luc reporter adenovirus, genomic DNA isolated from keratinocytes was used as a template for PCR. Primer sequences were as follows: involucrin promoter, 5′-CTCCATGTGTCATGGGATATG and 5′-TCAACCTGAAAGACAGAAGAG. The resultant PCR fragments cover from −2,467 to +1,239 base pairs of involucrin transcription site (

ChIP assay

Cells were grown to 50% confluency and then transduced with adenovirus expressing GFP-Brn2. After 2 day incubation, cells were cross-linked using 1% formaldehyde (Sigma) at 37°C for 10 min, rinsed two times with cold PBS, and then harvested in PBS containing protease inhibitors. ChIP assay was performed as previously described [43].

Cell growth analysis

For determination of cell growth, [3H]thymidine uptake assay was performed. Keratinocytes cells were seeded in 60-mm culture dish, transduced with adenovirus for overnight. Cells were replenished with fresh medium containing 1 µCi of [3H]thymidine (Amersham, Buckinghamshire, UK). Following incubation for the indicated time point, cells were washed twice with PBS and incubated with 0.1 N NaOH at room temperature. Radioactivity in cell lysates was measured by liquid scintillation counter.

Luciferase assay

Cells were grown at 50% confluency in a 12-well culture plate, then co-transduced with reporter adenovirus and Brn2 expressing adenovirus. After adenoviral transduction, cells were replenished with fresh medium. Cells were further incubated for 48 h, and then cellular extracts were prepared using cell lysis buffer. Luciferase activities were determined using Luciferase assay system (Promega, Madison, WI), according to the recommended protocol.

Intra-dermal injection of adenovirus in rat skin

Female Sprague Dawley (SD) rats, each weighing approximately 200 g, were used (Orient Bio, Gapyung, Korea). Fifty µl of recombinant virus solution (109 particles) prepared in PBS was injected intradermally into the dorsal skin of rats using a microsyringe with a 28-gauge hypodermic needle. The rats were sacrificed 7 day after intradermal injection and the dorsal skins were removed for histochemical analysis.

Chemotaxis assay

Chemotaxis assays were performed using a modified Boyden's chamber (Neuroprobe Inc., Gaithersburg, MD), as previously described [44]. Briefly, Jurkat T cells were suspended in RPMI and 1.5×105 of cells/ml was placed in the upper well of the chamber. Lower well contained adenovirally transduced keratinocytes. After incubation for 24 h at 37°C, non-migrated cells were discarded, and cells that migrated across the filter were counted.

Supporting Information

Figure S1

Dermal fibroblasts were transduced with recombinant adenoviruses for 6 h. After replenishing with fresh growth medium (DMEM supplemented with 10% FBS), cells were further cultured for 2 d. Total RNAs were isolated and RT-PCR was performed. Overexpression of Brn2 in fibroblasts resulted in increased expressions of IL-6 and IL-8, while the expressions of IGF and TGF-β were reduced.

(0.65 MB TIF)

Figure S2

Dermal fibroblasts were transduced with the indicated MOIs (multiplicity of infection) of recombinant adenoviruses for 6 h. After replenishing with fresh growth medium (DMEM supplemented with 10% FBS), cells were further cultured for 2 d. Culture medium were collected and the secreted IL-8 was determined using ELISA kit (Human IL-8 CytoSetTM, Biosource, Camarillo, CA). Overexpression of Brn2 led to increase of IL-8 secretion. Statistical significance was set at *P<0.05.

(0.75 MB TIF)

Figure S3

Dermal fibroblasts were transduced with 10 MOIs of recombinant adenoviruses for 6 h. Cells were replenished with fresh growth medium (DMEM supplemented with 10% FBS), and incubated for 1 d. Cells were then washed twice with PBS then refed with KGM and incubated for a further 2 d. Culture medium were collected and centrifuged. Supernatants were collected (conditioned medium, CM), and added to the keratinocyte culture at the 50% concentration. Keratinocytes were further incubated in the presence of 1 mCi of [3H]thymidine (Amersham, Buckinghamshire, UK) for the indicated time points. Cells were washed twice with PBS and incubated with 0.1 N NaOH at room temperature. Radioactivity in cell lysates was measured by liquid scintillation counter. Statistical significance was set at *P<0.05.

(0.93 MB TIF)


Competing Interests: The authors have declared that no competing interests exist.

Funding: This study was supported by a grant of the National Research Foundation of Korea (KRF-2008-314-E00152), and a grant of the Korea Health 21 R&D Project from the Korea Ministry of Health, Welfare and Family Affairs (01-PJ3-PG6-01GN12-0001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of manuscript.


1. Kalinin AE, Kajava AV, Steinert PM. Epithelial barrier function: assembly and structural features of the cornified cell envelope. Bioessays. 2002;24:789–800. [PubMed]
2. Steinert PM, Marekov LN. The proteins elafin, filaggrin, keratin intermediate filaments, loricrin, and small proline-rich proteins 1 and 2 are isodipeptide cross-linked components of the human epidermal cornified cell envelope. J Biol Chem. 1995;270:17702–17711. [PubMed]
3. Eckert RL, Crish JF, Efimova T, Dashti SR, Deucher A, et al. Regulation of involucrin gene expression. J Invest Dermatol. 2004;123:13–22. [PubMed]
4. Verrijzer CP, Van der Vliet PC. POU domain transcription factors. Biochim Biophys Acta. 1993;1173:1–21. [PubMed]
5. Wegner M, Drolet DW, Rosenfeld MG. POU-domain proteins: structure and function of developmental regulators. Curr Opin Cell Biol. 1993;5:488–498. [PubMed]
6. Ryan AK, Rosenfeld MG. POU domain family values, flexibility, partnerships and developmental codes. Genes Dev. 1997;11:1207–1225. [PubMed]
7. Fujii H, Hamada H. A CNS-specific POU transcription factor, Brn-2, is required for establishing mammalian neural cell lineages. Neuron. 1993;11:1197–1206. [PubMed]
8. Li P, He X, Gerrero MR, Mok M, Aggarwal A, et al. Spacing and orientation of bipartite DNA-binding motifs as potential functional determinants for POU domain factors. Genes Dev. 1993;7:2483–2496. [PubMed]
9. Schonemann MD, Ryan AK, McEvilly RJ, O'Connell SM, Arias CA, et al. Development and survival of the endocrine hypothalamus and posterior pituitary gland requires the neuronal POU domain factor Brn-2. Genes Dev. 1995;9:3122–3155. [PubMed]
10. Nakai S, Kawano H, Yudate T, Nishi M, Kuno J, et al. The POU domain trnscription factor Brn-2 is required for the determination of specific neuronal lineages in the hypothalamus of the mouse. Genes Dev. 1995;9:3109–3121. [PubMed]
11. Eisen T, Easty DJ, Bennett DC, Goding CR. The POU domain transcription factor Brn-2: elevated expression in malignant melanomaand regulation of melanocyte-specific gene expression. Oncogene. 1995;11:2157–2164. [PubMed]
12. Sturm RA, O'Sullivan BJ, Thomson JA, Jamshidi N, Pedley J, et al. Expression studies of pigmentation and POU-domain genes in human melanoma cells. Pigment Cell Res. 1994;7:235–240. [PubMed]
13. Cook AL, Donatien PD, Smith AG, Murphy M, Jones MK, et al. Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3. J Invest Dermatol. 2003;121:1150–1159. [PubMed]
14. Cook AL, Sturm RA. POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumourigenesis. Pigment Cell Melanoma Res. 2009;21:611–626. [PubMed]
15. Goodall J, Martinozzi S, Dexter TJ, Champeval D, Carreira S, et al. Brn-2 expression controls melanoma proliferation and is directly regulated by β-catenin. Mol Cell Biol. 2004;24:2915–2922. [PMC free article] [PubMed]
16. Goodall J, Wellbrock C, Dexter TJ, Roberts K, Marais R, et al. The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol Cell Biol. 2004;24:2923–2931. [PMC free article] [PubMed]
17. Seo EY, Namkung JH, Lee KM, Lee WH, Im M, et al. Analysis of calcium-inducible genes in keratinocytes using suppression subtractive hybridization and cDNA microarray. Genomics. 86:528–538. [PubMed]
18. Matthews JB, Scully CM, Potts AJ. Oral lichen planus: an immunoperoxidase study using monoclonal antibodies to lymphocyte subsets. Br J Dermatol. 1984;111:587–595. [PubMed]
19. Kilpi AM. Activation marker analysis of mononuclear cell infiltrates of oral lichen planus in situ. Scand J Dent Res. 1987;95:174–180. [PubMed]
20. Kilpi AM. Characterization of mononuclear cells of inflammatory infiltrates in oral tissues. A histochemical and immunohistochemical study of labial salivary glands in Sjögren's syndrome and of oral lesions in systemic lupus erythematosus and in lichen planus. Proc Finn Dent Soc. 1988;84:5–93. [PubMed]
21. Jungell P, Konttinen YT, Nortamo P, Malmström M. Immunoelectron microscopic study of distribution of T cell subsets in oral lichen planus. Scand J Dent Res. 1989;97:361–367. [PubMed]
22. Welter JF, Gali H, Crish J, Eckert RL. Regulation of human involucrin promoter activity by POU domain protein. J Biol Chem. 1996;271:14727–14733. [PubMed]
23. Delhase M, Castrillo JL, de la Hoya M, Rajas F, Hooghe-Peters EL. AP-1 and Oct-1 transcription factors down-regulate the expression of the human PIT1/GHF1 gene. J Biol Chem. 1996;271:32349–32358. [PubMed]
24. Jang SI, Karaman-Jurukovska N, Morasso MI, Steinert PM, Markova NG. Complex interactions between epidermal POU domain and activator protein 1 transcription factors regulate the expression of the profilaggrin gene in normal human epidermal keratinocytes. J Biol Chem. 2000;275:15295–15304. [PubMed]
25. Wakabayashi N, Itoh K, Wakabayashi J, Motohashi H, Noda S, et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet. 2003;35:238–245. [PubMed]
26. Hohl D. Expression patterns of loricrin in dermatological disorders. Am J Dermatopathol. 1993;15:20–27. [PubMed]
27. Eisenberg E, Murphy GF, Krutchkoff DJ. Involucrin as a diagnostic marker in oral lichenoid lesions. Oral surg oral Med Pathol. 1987;64:313–319. [PubMed]
28. Ichikawa E, Watanabe S, Takahashi H. Keratin and involucrin expression in discoid lupus erythematosus and lichen planus. Arch Dermatol Res. 1997;289:519–526. [PubMed]
29. Lee JJ, Kuo MY, Cheng SJ, Chiang CP, Jeng JH, et al. Higher expressions of p53 and proliferating cell nuclear antigen (PCNA) in atrophic oral lichen planus and patients with areca quid chewing. Oral surg Oral pathol Oral Radiol Endod. 2005;99:471–478. [PubMed]
30. Kikuchi A, Amagai M, Nishikawa T. Association of ras p21 with differentiation of epidermal keratinocytes in proliferating skin diseases. J Deramatol Sci. 1992;4:83–86. [PubMed]
31. Medenica M, Lorincz A. Lichen planus: an ultrastructural study. Acta Derm Venereol. 1977;57:55–62. [PubMed]
32. Hashimoto K. Apoptosis in lichen planus and several other dermatoses. Acta Dermatol Venereol. 1976;56:187–210. [PubMed]
33. Weedon D. Apoptosis in lichen planus. Clin Exp Dermatol. 1980;5:425–430. [PubMed]
34. Dekker NP, Lozada-Nur F, Lagenaur LA, MacPhail LA, Bloom CY, et al. Apoptosis-associated markers in oral lichen planus. J Oral Pathol Med. 1997;26:170–175. [PubMed]
35. Shimizu M, Higaki M, Kawashima M. The role of granzyme B-expressing CD8-positive T cells in apoptosis of keratinocytes in lichen planus. Arch Dermatol Res. 1997;289:527–532. [PubMed]
36. Bloor BK, Malik FK, Odell EW, Morgan PR. Quantitative assessment of apoptosis in oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88:187–195. [PubMed]
37. Neppelberg E, Johannessen AC, Jonsson R. Apoptosis in oral lichen planus. Eur J Oral Sci. 2001;109:361–364. [PubMed]
38. De Boer OJ, van der Loos CM, Teeling P, van der Wal AC, Teunissen MB. Immunohistochemical analysis of regulatory T cell markers FOXP3 and GITR on CD4+CD25+ T cells in normal skin and inflammatory dermatoses. J Histochem Cytochem. 2007;55:891–898. [PubMed]
39. Ishii T. Immunohistochemical demonstration of T cell subsets and accessory cells in oral lichen planus. J Oral Pathol. 1987;16:356–361. [PubMed]
40. Yoon HK, Sohn KC, Lee JS, Kim YJ, Bhak J, et al. Prediction and evaluation of protein-protein interaction in keratinocyte differentiation. Biochem Biophys Res Commun. 2008;377:662–667. [PubMed]
41. Sohn KC, Shi G, Jang S, Choi DK, Lee Y, et al. Pitx2, a beta-catenin-regulated transcription factor, regulates the differentiation of outer root sheath cells cultured in vitro. J Dermatol Sci. 2009;54:6–11. [PubMed]
42. Tollefson AE, Kuppuswamy M, Shashkova EV, Doronin K, Wold WS. Preparation and titration of CsCl-banded adenovirus stocks. Methods Mol Med. 2007;130:223–235. [PubMed]
43. Fajas L, Landsberg RL, Huss-Garcia Y, Sardet C, Lees JA, et al. E2Fs regulate adipocyte differentiation. Dev Cell. 2002;3:39–49. [PubMed]
44. Piao YJ, Lee CH, Zhu MJ, Kye KC, Kim JM, et al. Involvement of urokinase-type plasminogen activator in sphingosylphosphorylcholine-induced angiogenesis. Exp Dermatol. 2005;14:356–362. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science